Trial Profile

A Randomized, Multicenter, Open-label, Phase II Study of Platinum-Containing Chemotherapy and Sintilimab With or Without Autologous Cytokine-induced Killer Cell Immunotherapy in Stage IV Non-Small Cell Lung Cancer Subjects

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cytokine-induced killer cell therapy (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary) ; Sintilimab (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms CCICC-002b

13 Mar 2025 According to a ClinicalTrial.gov record, the protocol was amended to change the primary end point form Overall response rate upto 2 year to Objective Response Rate (ORR) up to 24 month.
13 Mar 2025 Planned End Date changed from 1 Dec 2023 to 31 Dec 2026.
13 Mar 2025 Status changed to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com